Top Anti Cancer Imported Medicine Drugs in India - Pharama Five
Help Desk :+916374297988

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org

Best Exkivity (Mobocertinib) Medicine in India

Buy Exkivity (Mobocertinib) Medicine in India

Exkivity (Mobocertinib)

Medicine name : Exkivity

Generic name : Mobocertinib

Manufactured By : Takeda

Indications : metastatic NSCLC (With EGFR exon 20 insertion mutations)

Medicine Description : Exkivity is an oral tyrosine kinase inhibitor (TKI) for EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC). It targets abnormal EGFR proteins to slow tumor progression. Side effects include diarrhea, heart rhythm abnormalities, nausea, and fatigue. Patients require regular ECG monitoring due to potential cardiac risks.

Product Introduction

Exkivity (Mobocertinib) is a targeted anticancer medicine used to treat certain adults with non-small cell lung cancer (NSCLC) that has specific EGFR exon 20 insertion mutations and has progressed after platinum-based chemotherapy. Mobocertinib works by blocking abnormal EGFR signaling involved in the growth and survival of cancer cells, helping to slow tumor growth and disease progression.

Exkivity (Mobocertinib) should be taken exactly as prescribed by your doctor. The recommended dose and treatment duration depend on your condition and response to treatment. It may be taken with or without food and should be taken regularly as directed. Regular medical check-ups and laboratory tests, including heart monitoring, may be required during treatment.

Common side effects of Exkivity (Mobocertinib) may include diarrhea, rash, nausea, vomiting, decreased appetite, dry skin, muscle or joint pain, fatigue, and inflammation around the nails. Mobocertinib can also cause serious heart rhythm problems and lung inflammation. Inform your doctor if any side effect becomes severe, persistent, or causes concern. Seek medical attention promptly if you develop severe or persistent diarrhea, new or worsening breathing difficulties, fainting, dizziness, or a fast or irregular heartbeat.

Uses Of Exkivity (Mobocertinib)

Treatment of EGFR Exon 20 Insertion Mutation-Positive NSCLC

Benefits Of Exkivity

Exkivity (Mobocertinib) is a targeted treatment used for adults with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. It works by blocking abnormal EGFR signaling that promotes cancer cell growth and survival. This helps inhibit the growth of cancer cells and may slow the progression of advanced NSCLC.

Side Effects Of Exkivity (Mobocertinib)

Some side effects of Exkivity (Mobocertinib) may improve as your body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Exkivity (Mobocertinib)

  • Diarrhea
  • Rash
  • Nausea
  • Vomiting
  • Decreased appetite
  • Dry skin
  • Fatigue
  • Muscle or joint pain
  • Inflammation around the nails
  • Mouth sores
How To Use Exkivity

Exkivity (Mobocertinib) should be taken exactly as prescribed by your doctor. It may be taken with or without food and should be taken at the same time each day. Swallow it whole with water and do not chew, crush, or open it. Do not change the dose or stop treatment without consulting your doctor.

How Exkivity (Mobocertinib) Works

Exkivity (Mobocertinib) is a targeted therapy that blocks abnormal epidermal growth factor receptor (EGFR) signaling caused by EGFR exon 20 insertion mutations. These abnormal signals can promote the growth and survival of cancer cells. By inhibiting EGFR activity, Mobocertinib helps slow the growth and spread of EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).

Safety Advice

AlcoholCONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Exkivity (Mobocertinib).

PregnancyCONSULT YOUR DOCTOR

Exkivity (Mobocertinib) may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment with Exkivity (Mobocertinib) and for the recommended period after the final dose. Consult your doctor for guidance.

DrivingCONSULT YOUR DOCTOR

Exkivity (Mobocertinib) may cause fatigue, dizziness, or other effects that can affect alertness. Avoid driving if these symptoms occur.

KidneyCAUTION

Inform your doctor if you have kidney problems before starting Exkivity (Mobocertinib). Your doctor may monitor your kidney function during treatment.

LiverCAUTION

Tell your doctor if you have liver problems. Your doctor may monitor liver function and adjust treatment if necessary.

Quick Tips
  • Take Exkivity (Mobocertinib) exactly as prescribed by your doctor and do not change or stop treatment without medical advice.
  • Inform your doctor immediately if you develop new or worsening breathing difficulties, as this may indicate a serious lung problem.
  • Seek medical attention if you experience fainting, dizziness, a fast or irregular heartbeat, or other symptoms that may indicate heart rhythm changes.
  • Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
  • Attend regular medical check-ups and heart monitoring as recommended during treatment.
  • Read More About - Exkivity (Mobocertinib) from Pharma Five.
Faq

General Question

Exkivity Medicine (Mobocertinib) is a prescription drug used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations, particularly in patients who have previously received chemotherapy.

Exkivity Medicine is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It works by targeting and blocking specific mutations in the EGFR protein to slow the growth and spread of cancer cells.

Exkivity Medicine is prescribed for adults with locally advanced or metastatic NSCLC that is positive for EGFR exon 20 insertion mutations, especially after chemotherapy has been ineffective.

Exkivity Medicine is taken orally in tablet form, typically once daily with or without food, as prescribed by your doctor.

Common side effects of Exkivity Medicine include diarrhea, rash, nausea, fatigue, and decreased appetite.

Yes, Exkivity Medicine can cause serious side effects, including severe diarrhea, liver problems, heart issues, or eye problems. Immediate medical attention should be sought if any of these occur.

Exkivity Medicine is usually taken as long as it is effective and well-tolerated, or until your doctor advises discontinuation based on your treatment response.

It is advisable to avoid alcohol while taking Exkivity Medicine, as it could worsen side effects such as dizziness, fatigue, or gastrointestinal issues.

Exkivity Medicine may harm an unborn baby and is not recommended during pregnancy. Women should use effective contraception while taking this medication.

Yes, Exkivity Medicine can interact with certain medications, including other cancer therapies, antibiotics, antifungals, and anticonvulsants. Always inform your doctor of all the medications you are taking.

If you miss a dose, take it as soon as you remember, unless its close to the time for your next dose. Do not take two doses at once.

Yes, Exkivity Medicine can be taken with or without food. Taking it with food may help reduce potential stomach upset.

Avoid exposure to sunlight, as Exkivity may increase sensitivity to the sun. Regular monitoring of liver function and gastrointestinal health is also recommended during treatment.

Store Exkivity Medicine at room temperature, away from moisture, heat, and out of reach of children.

Exkivity Medicine is available by prescription through pharmacies or specialty drug providers. Speak with your doctor or pharmacist to find the best source for obtaining the medication. Pharma Five assists in its procurement.